Evelo Biosciences Inc. (EVLO)

$0.00

up-down-arrow $-0.04 (-99.75%)

As on 16-Jun-2026 16:00EDT

Market cap

info icon

$0 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

3.5

Div. Yield

info icon

0 %

Evelo Biosciences (EVLO) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 0.00 High: 0.00

52 Week Range

Low: 0.00 High: 0.00

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $-70 Mln

  • ROEROE information

    -62.3 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    -0.4

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-83.8

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    18,982,837

8 Years Aggregate

CFO

$-499.56 Mln

EBITDA

$-493.16 Mln

Net Profit

$-593.61 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Evelo Biosciences (EVLO)
-- -- -- -- -96.1 -95.0 --
BSE Sensex*
-8.9 2.5 2.2 -5.7 6.8 8.0 11.3
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 16-Jun-2026  |  *As on 17-Jun-2026  |  #As on 26-Oct-2023
Company
2023
2022
2021
2020
2019
Evelo Biosciences (EVLO)
-99.8 -73.5 -49.8 197.8 -68.8
S&P Small-Cap 600
13.9 -17.4 25.3 9.6 20.9
BSE Sensex
18.7 4.4 22.0 15.8 14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peers

View Details
Company
Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Evelo Biosciences (EVLO)
0.0 0.0 0.0 -82.4 -- -- -- 3.5
284.7 37,764.0 4,286.9 577.2 20.3 88.2 70.9 35.1
52.6 13,354.5 2,375.5 833.4 41.5 40.7 17.6 6.9
130.3 17,452.8 1,080.2 -433.2 -39.8 -- -- 55.7
173.4 29,936.9 16,632.0 1,385.0 14.1 22.3 22.3 4.9
506.3 11,084.5 1,132.5 -309.4 -25.0 -52.9 -- 20.4
465.4 13,347.1 2,678.3 460.4 21.3 103.2 29.4 22.3
615.3 64,176.2 14,919.6 4,423.4 34.9 14.2 14.9 2.0
555.2 23,174.2 3,169.8 1,287.4 51.3 20.6 20.2 3.9
464.0 112,924.4 12,255.1 4,338.3 32.0 23.7 26.4 5.8

Shareholding Pattern

View Details
loading...
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Evelo Biosciences (EVLO)

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate,...  which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. 

  • President, Secretary, Principal Executive, Financial and Accounting Officer & Director

    Mr. Craig R. Jalbert CIRA

  • President, Secretary, Principal Executive, Financial and Accounting Officer & Director

    Mr. Craig R. Jalbert CIRA

  • Headquarters

    Cambridge, MA

  • Website

    https://www.evelobio.com

Edit peer-selector-edit
loading...
loading...

FAQs for Evelo Biosciences (EVLO)

The share price of Evelo Biosciences Inc (EVLO) is $0.00 (NASDAQ) as of 16-Jun-2026 16:00 EDT. Evelo Biosciences Inc (EVLO) has given a return of -96.08% in the last 3 years.

Since, TTM earnings of Evelo Biosciences Inc (EVLO) is negative, P/E ratio is not available.
The P/B ratio of Evelo Biosciences Inc (EVLO) is 3.51 times as on 12-Jun-2026, a 15 discount to its peers’ median range of 4.14 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2022
-0.08
-1.77
2021
-0.13
1.87
2020
-0.30
0.93
2019
-0.08
0.11
2018
-0.38
0.15

The 52-week high and low of Evelo Biosciences Inc (EVLO) are Rs 0.00 and Rs 0.00 as of 17-Jun-2026.

Evelo Biosciences Inc (EVLO) has a market capitalisation of $ 0 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.

Before investing in Evelo Biosciences Inc (EVLO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.